Computational study of influence of diffuse basis functions on geometry optimization and spectroscopic properties of Losartan potassium (cas 12475-99-8)
-
Add time:08/15/2019 Source:sciencedirect.com
The work was aimed at investigating the influence of diffusion of basis functions on the geometry optimization of molecule of losartan in acidic and salt form. Spectroscopic properties of losartan potassium were also calculated and compared with experiment. Density functional theory method with various basis sets: 6-31G(d,p) and its diffused variations 6-31G(d,p)+ and 6-31G(d,p)++ was used. Application of diffuse basis functions in geometry optimization resulted in significant change of total molecule energy. Total molecule energy of losartan potassium decreased by 112.91 kJ/mol and 114.32 kJ/mol for 6-31G(d,p)+ and 6-31G(d,p)++ basis sets, respectively. Almost the same decrease was observed for losartan: 114.99 kJ/mol and 117.08 kJ/mol respectively for 6-31G(d,p)+ and 6-31G(d,p)++ basis sets. Further investigation showed significant difference within geometries of losartan potassium optimized with investigated basis sets. Application of diffused basis functions resulted in average 1.29 Å difference in relative position between corresponding atoms of three obtained geometries. Similar study taken on losartan resulted in only average 0.22 Å of dislocation. Extensive analysis of geometry changes in molecules obtained with diffused and non-diffuse basis functions was carried out in order to elucidate observed changes. The analysis was supported by electrostatic potential maps and calculation of natural atomic charges. UV, FT-IR and Raman spectra of losartan potassium were calculated and compared with experimental results. No crucial differences between Raman spectra obtained with different basis sets were observed. However, FT-IR spectra of geometry of losartan potassium optimized with 6-31G(d,p)++ basis set resulted in 40% better correlation with experimental FT-IR spectra than FT-IR calculated with geometry optimized with 6-31G(d,p) basis set. Therefore, it is highly advisable to optimize geometry of molecules with ionic interactions using diffuse basis functions when accuracy of results is a priority.
We also recommend Trading Suppliers and Manufacturers of Losartan potassium (cas 12475-99-8). Pls Click Website Link as below: cas 12475-99-8 suppliers
Prev:Significance of Metabolites in Bioequivalence: Losartan potassium (cas 12475-99-8) as a Case Study
Next:A clean photometric method for the determination of Losartan potassium (cas 12475-99-8) in pharmaceuticals exploiting light scattering effect and employing a multicommuted flow analysis approach) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Molecular insight into atypical instability behavior of fixed-dose combination containing amlodipine besylate and Losartan potassium (cas 12475-99-8)08/19/2019
- Formulation and evaluation of sublingual tablets of Losartan potassium (cas 12475-99-8)08/18/2019
- A statistical study on the development of micro particulate sustained drug delivery system for Losartan potassium (cas 12475-99-8) by 32 factorial design approach08/17/2019
- A clean photometric method for the determination of Losartan potassium (cas 12475-99-8) in pharmaceuticals exploiting light scattering effect and employing a multicommuted flow analysis approach08/16/2019
- Significance of Metabolites in Bioequivalence: Losartan potassium (cas 12475-99-8) as a Case Study08/14/2019
- Utilizing Guar Gum for Development of “Tabs In Cap’ System of Losartan potassium (cas 12475-99-8) for Chronotherapeutics08/13/2019
- Design and evaluation of controlled release Losartan potassium (cas 12475-99-8) microcapsules08/12/2019
- Comparison of Fixed-dose Combinations of Amlodipine/Losartan potassium (cas 12475-99-8)/Chlorthalidone and Amlodipine/Losartan potassium (cas 12475-99-8) in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan potassium (cas 12475-99-8): A Randomized, Double-blind, Multicenter, Phase III Study08/11/2019
- Modulating effect of Losartan potassium (cas 12475-99-8) on the mutagenicity and recombinogenicity of doxorubicin in somatic cells of Drosophila melanogaster08/10/2019
-
Health and Chemical more >
-
Related Products
- Losartan carboxylic acid
- Losartan potassium
- Potassium (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylate
- Potassium (4-formylphenyl)trifluoroborate
- Potassium (bromomethyl)trifluoroborate
- Potassium (R)-((3-ethoxy-1-methyl-3-oxoprop-1-enyl)amino)(4-hydroxyphenyl)acetate
- Potassium (R)-(4-hydroxyphenyl)((3-methoxy-1-methyl-3-oxoprop-1-enyl)amino)acetate
- Potassium (R)-[(3-ethoxy-1-methyl-3-oxoprop-1-enyl)amino]phenylacetate
- Potassium [(cyanomethyl)thio]acetate
- Potassium 1,2,3,6-tetrahydro-5-nitro-2,6-dioxopyrimidine-4-carboxylate


